期刊文献+

整合素β_1信号通路参与非小细胞肺癌吉非替尼获得性耐药 被引量:3

Integrin β_1 participates in acquired resistance to gefitinib in non-small cell lung cancer
下载PDF
导出
摘要 目的探讨整合素β1及其下游信号转导通路在非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)吉非替尼获得性耐药中的作用。方法以人肺腺癌细胞株PC-9和吉非替尼耐药株PC-9/G作为研究对象,免疫印迹分析检测整合素β1、Akt、磷酸化Akt蛋白的表达;用MTT法检测吉非替尼和(或)磷脂酰肌醇3激酶(PI3K)抑制剂LY294002、细胞外调节蛋白激酶(ERK)抑制剂PD98059对细胞增殖的影响;用AnnexinⅤ/PI试剂盒和TUNEL试剂盒检测细胞凋亡。结果吉非替尼耐药株PC-9/G高表达整合素β1,RNA干扰抑制整合素β1表达能够抑制PC-9/G细胞的生长和促进凋亡。PC-9/G细胞中吉非替尼对Akt磷酸化的抑制作用弱于PC-9细胞,RNA干扰抑制整合素β1表达后Akt的磷酸化水平降低。ERK抑制剂PD98059不能恢复PC-9/G细胞对吉非替尼的敏感性,PI3K抑制剂LY294002能恢复PC-9/G细胞对吉非替尼的敏感性。结论整合素β1过表达可以通过PI3K途径激活下游信号分子,这可能是一种重要的EGFR-TKI耐药机制。 Objective To explore the role of integrin β1 and relevant signaling pathway in acquired resistance to epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI) gefitinib in non-small cell lung cancer(NSCLC). Methods Human lung adenocarcinoma cell line PC-9 and gefitinib-resistant PC-9/G cell lines were used in the present study.Western blotting analysis was used to examine the expression of integrin β1,Akt and phospho-Akt protein.The inhibitory effects of gefitinib and/or phosphoinositide 3-kinase(PI3K) inhibitor LY294002 and extracellular regulated protein kinases(ERK) inhibitor PD98059 on cellular proliferation were tested by MTT assay.Cell apoptosis was analyzed by Annexin Ⅴ/PI and TUNEL method.Results Overexpression of integrin β1 was observed in PC-9/G cell line.Silencing integrin β1 by RNAi method inhibited the proliferation and promoted apoptosis of PC-9/G cells.The inhibitory effect of gefitinib against Akt phosphorylation in PC-9/G cells was weaker than that in PC-9 cells.Knockdown of integrin β1 with RNAi decreased the phosphorylation level of Akt.ERK inhibitor PD98059 failed to restore the sensitivity of PC-9/G cells to gefitinib.PI3K inhibitor LY294002 could restore the sensitivity of PC-9/G cells to gefitinib.Conclusion It is suggested that overexpressed integrin β1 can activate the downstream signaling pathways through PI3K,which may be an important mechanism for resistance to EGFR-TKIs.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2012年第6期585-589,共5页 Academic Journal of Second Military Medical University
基金 国家自然科学基金(30873023)~~
关键词 肿瘤抗药性 表皮生长因子受体 酪氨酸激酶抑制剂 整合素 neoplasm drug resistance; epidermal growth factor receptor; tyrosine kinase inhibitor; integrin
  • 相关文献

参考文献22

  • 1Laskin J J, Sandier A B. Epidermal growth factor receptor: a promising target in solid tumours[J]. Cancer Treat Rev, 2004, 30:1-17.
  • 2Zhou C,Wu Y L,Chen G,Feng J,Liu X Q,Wang C,et al. Erlo- tinib versus chelmnotherapy as first-line treatment for patients with advanced EGFR mutation positive non-small-cell lung cancer (OPTIMAL,CTONG-0802) : a multicentre,open-label, randornised,phase 3 study[J]. Lancet Oncol, 2011, 12: 735- 742.
  • 3Thomson S, Buck E,Petti F, Griffin G, Brown E, Ramnarine N, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non small-cell lung carcinoma cell lines and xeno- grafts to epidermal growth factor receptor inhibition[J].Cancer Res, 2005,65,9455-9462.
  • 4Shintani Y,Maeda M,Chaika N,Johnson K R,Wheeloek M J. Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling [J]. Am J Respir Cell Mol Biol,2008,38:95-104.
  • 5Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel in- duced apoptosis in breast cancer eells[J]. Oncogene, 2001,20 : 4995-5004.
  • 6Damiano J S,Cress A E,Hazlehurst L A,Shtil A A,Dalton W S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines[J]. Blood, 1999,93 : 1658-1667.
  • 7Emmons M F,Gebhard A W, Nair R R, Baz R, McLaughlin M L, Cress A E, et al. Acquisition of resistance toward HYD1 cor- relates with a reductioa in cleaved a4 integrin expression and a compromised CAM-DR phenotype[J]. Mol Cancer Ther, 20ll, 10,2257-2266.
  • 8Sethi T, Rintoul R C, Moore S M, MacKinnon A C, Salter D, Choo C, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis., a mechanism for small cell lung cancer growth and drug resistance in vivo [J]. Nat Med, 1999,5:662-668.
  • 9鞠立霞,周彩存,唐亮,赵印敏,杨晓君,粟波,孟淑燕,李玮,严令华,丁永梅.吉非替尼获得性耐药的非小细胞肺癌细胞株PC9/AB2相关耐药机制研究[J].中华结核和呼吸杂志,2010,33(5):354-358. 被引量:12
  • 10张学兰,周彩存,鞠立霞.整合素β_1表达上调对非小细胞肺癌吉非替尼耐药的影响[J].肿瘤,2011,31(6):483-488. 被引量:7

二级参考文献42

  • 1Jackman DM,Yeap BY,Sequist LV,et al.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.Clin Cancer Res,2006,12:3908-3914.
  • 2Inoue A,Suzuki T,Fukuhara T,et al.Prospective phase Ⅱ study of gefitinib for chemotherapy-naive patients with advanced nonsmall-cell lung cancer with epidermal growth factor receptor gene mutations.J Clin Oncol,2006,24:3340-3346.
  • 3Yoshida K,Yatabe Y,Park JY,et al.Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.J Thorac Oncol,2007,2:22-28.
  • 4Rosell R,Taron M,Sanchez JJ,et al.Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors.Future Oncol,2007,3:277-283.
  • 5Koizumi F,Shimoyama T,Taguchi F,et al.Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.Int J Cancer,2005,116:36-44.
  • 6Carlynn WP,Joseph AH,Lester JL,et al.Detection of EGFRand HER2-activating mutations in squamous cell carcinoma involving the head and neck.Modern Pathology,2006,19:634-640.
  • 7Pao W,Miller VA,Politi KA,et al.Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.Plos Med,2005,2:73.
  • 8Bean J,Brennan C,Shih JY,et al.MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.Proc Natl Acad Sci U S A,2007,104:20932-20937.
  • 9Velling T,Stefansson A,Johansson S.EGFR and β1 integrins utilize different signaling pathways to activate Akt.Exp Cell Res,2008,314:309-316.
  • 10Miyamoto S,Teramoto H,Gutkind JS,et al.Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation:roles of integrin aggregation and occupancy of receptors.J Cell Biol,1996,135:1633-1642.

共引文献22

同被引文献19

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部